Madrigal Pharmaceuticals, Inc. (1MDGL)
Summary
1MDGL Chart
Madrigal's Rezdiffra Hits $1.3B Run Rate as MASH Pipeline Expands
Madrigal Pharmaceuticals NASDAQ: MDGL said Rezdiffra continued to post strong commercial growth in the second quarter of 2026, while the company expanded its development pipeline around the MASH therapy and prepared for several potential clinical catalysts.
Madrigal Pharmaceuticals, Inc. (MDGL) Presents at Canaccord Genuity's 46th Annual Growth Conference Transcript
Madrigal Pharmaceuticals, Inc. (MDGL) Presents at Canaccord Genuity's 46th Annual Growth Conference Transcript
MDGL Stock Down Despite Q2 Beat, MASH Drug Drives Top-Line Y/Y Growth
Madrigal beats Q2 estimates as Rezdiffra sales lift revenues 71% year over year, but shares fall as investors weigh slower commercial growth.
Madrigal Pharmaceuticals, Inc. (1MDGL) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Madrigal Pharmaceuticals, Inc. ever had a stock split?
Madrigal Pharmaceuticals, Inc. Profile
| Biotechnology Industry | Healthcare Sector | William J. Sibold CEO | XMIL Exchange | US5588681057 ISIN |
| US Country | 915 Employees | 25 Jul 2016 Last Dividend | 25 Jul 2016 Last Split | 6 Feb 2007 IPO Date |
Overview
Madrigal Pharmaceuticals, Inc. is a forward-thinking clinical-stage biopharmaceutical company based in West Conshohocken, Pennsylvania. With a primary focus on addressing the significant unmet medical needs in non-alcoholic steatohepatitis (NASH), Madrigal Pharmaceuticals, Inc. is at the forefront of developing innovative therapeutic solutions. NASH, a more severe form of non-alcoholic fatty liver disease (NAFLD), is a major cause of liver disease worldwide, lacking effective FDA-approved treatments. This places Madrigal Pharmaceuticals in a critical position to potentially transform the treatment landscape for this challenging condition. The company’s commitment to pioneering research and clinical development underscores its dedication to improving patient outcomes in the NASH domain.
Products and Services
- Resmetirom
Madrigal Pharmaceuticals’ lead product candidate, resmetirom, is a testament to the company’s innovative approach in targeting complex liver diseases. Resmetirom is a liver-directed thyroid hormone receptor beta agonist specifically designed to address the root causes of NASH. The mechanism of action involves modulating liver fat metabolism, reducing liver fat, inflammation, and fibrosis, which are critical factors in the progression of NASH. Currently in Phase 3 clinical trials, resmetirom has shown promise in early studies, offering hope for a potential breakthrough therapy for patients suffering from this life-threatening condition. The ongoing research and development of resmetirom reflect Madrigal Pharmaceuticals’ dedication to scientific excellence and a patient-centered approach to healthcare.
